Artificial Intelligence in Pharmaceutical Sciences
Mingkun Lu,
Jiayi Yin,
Qi Zhu,
Gaole Lin,
Minjie Mou,
Fuyao Liu,
Ziqi Pan,
Nanxin You,
Xichen Lian,
Fengcheng Li,
Hongning Zhang,
Lingyan Zheng,
Wei Zhang,
Hanyu Zhang,
Zihao Shen,
Zhen Gu,
Honglin Li,
Feng Zhu
Affiliations
Mingkun Lu
College of Pharmaceutical Sciences & The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China; Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Alibaba–Zhejiang University Joint Research Center of Future Digital Healthcare, Hangzhou 330110, China
Jiayi Yin
College of Pharmaceutical Sciences & The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China
Qi Zhu
College of Pharmaceutical Sciences & The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China
Gaole Lin
College of Pharmaceutical Sciences & The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China
Minjie Mou
College of Pharmaceutical Sciences & The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China
Fuyao Liu
College of Pharmaceutical Sciences & The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China
Ziqi Pan
College of Pharmaceutical Sciences & The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China
Nanxin You
College of Pharmaceutical Sciences & The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China
Xichen Lian
College of Pharmaceutical Sciences & The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China
Fengcheng Li
College of Pharmaceutical Sciences & The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China
Hongning Zhang
College of Pharmaceutical Sciences & The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China
Lingyan Zheng
College of Pharmaceutical Sciences & The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China; Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Alibaba–Zhejiang University Joint Research Center of Future Digital Healthcare, Hangzhou 330110, China
Wei Zhang
College of Pharmaceutical Sciences & The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China
Hanyu Zhang
College of Pharmaceutical Sciences & The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China
Zihao Shen
Shanghai Key Laboratory of New Drug Design, East China University of Science and Technology, Shanghai 200237, China; Innovation Center for AI and Drug Discovery, East China Normal University, Shanghai 200062, China
Zhen Gu
College of Pharmaceutical Sciences & The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China
Honglin Li
Shanghai Key Laboratory of New Drug Design, East China University of Science and Technology, Shanghai 200237, China; Innovation Center for AI and Drug Discovery, East China Normal University, Shanghai 200062, China; Lingang Laboratory, Shanghai 200031, China; Corresponding authors.
Feng Zhu
College of Pharmaceutical Sciences & The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China; Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Alibaba–Zhejiang University Joint Research Center of Future Digital Healthcare, Hangzhou 330110, China; Corresponding authors.
Drug discovery and development affects various aspects of human health and dramatically impacts the pharmaceutical market. However, investments in a new drug often go unrewarded due to the long and complex process of drug research and development (R&D). With the advancement of experimental technology and computer hardware, artificial intelligence (AI) has recently emerged as a leading tool in analyzing abundant and high-dimensional data. Explosive growth in the size of biomedical data provides advantages in applying AI in all stages of drug R&D. Driven by big data in biomedicine, AI has led to a revolution in drug R&D, due to its ability to discover new drugs more efficiently and at lower cost. This review begins with a brief overview of common AI models in the field of drug discovery; then, it summarizes and discusses in depth their specific applications in various stages of drug R&D, such as target discovery, drug discovery and design, preclinical research, automated drug synthesis, and influences in the pharmaceutical market. Finally, the major limitations of AI in drug R&D are fully discussed and possible solutions are proposed.